• Explore /
  • Poster
  • / Prevalence of historical medical conditions or comorbidities with potential role in clinical decision making related to suitability of immuno-oncologic plus IV antiangiogenic therapy in newly diagnosed first-line unresectable hepatocellular carcinoma in the United States.

Prevalence of historical medical conditions or comorbidities with potential role in clinical decision making related to suitability of immuno-oncologic plus IV antiangiogenic therapy in newly diagnosed first-line unresectable hepatocellular carcinoma in the United States.

Abstract Poster

Authors

null

Tammy Schuler

Cardinal Health Specialty Solutions, Dublin, OH;

Tammy Schuler , Leonardo Passos Chaves , Shital Kamble , Emily Bland , Bruce A. Feinberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 511)

DOI

10.1200/JCO.2023.41.4_suppl.511

Abstract #

511

Poster Bd #

B1

Abstract Disclosures

Similar Posters

First Author: Neehar Parikh

Poster

2024 ASCO Annual Meeting

Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.

Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.

First Author: Ghassan K. Abou-Alfa

First Author: Kevin Kim

First Author: Tanios S. Bekaii-Saab